Founder, CSO and CBDO of Histogen, focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions

• Developed method for creating a hypoxia-induced multipotent stem cell which simultaneously produces a novel soluble and insoluble extracellular matrix, each of which has multiple aesthetic and therapeutic applications. The lead drug is in mid stage clinical trials for hair growth and the skin care product, ReGenica, was acquired by Allergan for the medical market in 2017

Dr. Naughton has spent nearly 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies

Co-founder of Advanced Tissue Sciences and co-inventor of its core technology. At ATS, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. Dr. Naughton oversaw the design and development of the world’s first up-scaled manufacturing facility for tissue engineered products, established corporate development and marketing partnerships with companies including Smith & Nephew, Ltd., Medtronic and Inamed Corporation, was pivotal in raising over $350M from the public market and corporate partnerships, and brought four products from concept through FDA approval and market launch

Extensively published and a frequent speaker in the field of tissue engineering

Received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering